$远藤制药(ENDP)$
ENDP's 2Q delivered against low expectations which combined with MYL's generic Lidoderm approval remove two important headwinds.From here we see
(i) several important P&L drivers setting up nicely
(ii)potential FDA approvals inflection that can boost sentiment around thePar deal and (iii) more anticipated M&A ahead